AVITA Medical (RCEL) Q2 2024 earnings summary

Executive summary

• Q2 2024 commercial revenue reached $15.2 million, up 29% year-over-year, driven by deeper market penetration, new product launches, and expanded account adoption for full-thickness skin defects.

• Enhanced coverage strategies, RECELL GO and PermeaDerm launches, and a strategic transformation to offer a continuum of wound care supported growth.

• Strengthened management with a new SVP of U.S. Commercial Sales and expanded international presence through new distribution agreements.

• Entered exclusive agreements for new dermal matrices, including Regenity Biosciences, and launched PermeaDerm in the U.S.

• FDA approved RECELL GO in May 2024; RECELL GO mini PMA supplement submitted in June, with anticipated approval by year-end.

Financial highlights

• Q2 2024 commercial revenue: $15.2 million, up from $11.8 million in Q2 2023.

• Gross profit margin improved to 86.2% from 81.2% in Q2 2023.

• Operating expenses rose to $28.7 million, mainly due to increased sales and marketing costs.

• Net loss was $15.4 million ($0.60 per share), compared to $10.4 million ($0.41 per share) in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $54.1 million as of June 30, 2024.

Outlook and guidance

• Q3 2024 commercial revenue guidance set at $19–$20 million, representing 40–48% year-over-year growth.

• Full-year 2024 revenue guidance revised to $68–$70 million, reflecting over 37% annual growth.

• Targeting cash flow break-even and GAAP profitability by Q3 2025.

• Anticipate FDA approval of RECELL GO mini and 510(k) clearance for Regenity dermal matrix by year-end.